Pacira BioSciences is exploding higher today following the announcement that Viatris Inc. has agreed to acquire the company for $36.50 per share in cash. This deal, valued at $1.65 billion, aims to bolster Viatris's innovative medicines portfolio by integrating Pacira's high-margin, non-opioid pain therapies, EXPAREL and ZILRETTA. While an investor rights law firm has initiated an investigation into whether the sale price is fair to shareholders, the acquisition news remains the primary driver of the stock's significant upward move. This development follows a positive announcement from earlier in the week regarding an exclusive agreement with Molteni Farmaceutici to expand the commercial reach of EXPAREL into the European Union and the United Kingdom.